The Early Treatment for Retinopathy of Prematurity Study (ETROP)
Launched by NATIONAL EYE INSTITUTE (NEI) · Oct 26, 2001
Trial Information
Current as of June 30, 2025
Unknown status
Keywords
ClinConnect Summary
At age 5 1/2 years, the oldest age for which follow-up data are available, children with threshold ROP who were enrolled in the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) -- Outcome Study showed fewer treated eyes (31.5 percent) than control eyes (48 percent) that were blind (P\<0.001). Of those eyes that had a favorable structural outcome, with or without retinal ablation (cryotherapy to destroy the fringe of the retina through freezing), only a small percentage had best corrected visual acuity better than or equal to 20/40 at age 5 1/2 years (13 percent in the treated group; 17...
Gender
ALL
Eligibility criteria
- • Infants \<1251 grams birthweight born at participating centers and/or examined by 42 days of life are eligible. The early treatment trial requires that an infant have prethreshold retinopathy of prematurity (ROP).
About National Eye Institute (Nei)
The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
San Antonio, Texas, United States
Rochester, New York, United States
San Antonio, Texas, United States
Columbus, Ohio, United States
New Orleans, Louisiana, United States
Palo Alto, California, United States
San Francisco, California, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Louisville, Kentucky, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Dearborn, Michigan, United States
Minneapolis, Minnesota, United States
St. Louis, Missouri, United States
Buffalo, New York, United States
New York, New York, United States
Shirley, New York, United States
Durham, North Carolina, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Patients applied
Trial Officials
William V. Good, M.D.
Study Chair
Smith-Kettlewell Eye Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials